Columbia, Maryland, January 18, 2018 – WellDoc®, a leading digital therapeutic company, announced today that John L. Brooks, III, a recognized life-sciences executive with more than 40 years of experience, will join the company’s team as a strategic advisor.
“We’re pleased that John has chosen to work with us as an advisor,” said WellDoc President and CEO Kevin McRaith. “His experience as a life sciences executive, specifically in the diabetes space, will be a great asset to WellDoc.”
Mr. Brooks is the Managing Director of Healthcare Capital LLC, an investment company that takes an advisory role with early-stage life sciences companies, with a specific focus on novel solutions for obesity, prediabetes and diabetes. Additionally, he is a Director at the Pittsburgh Life Sciences Greenhouse, which oversees two accelerators. He also serves on other corporate boards including Cellnovo Group SA, Thermalin, Inc., Hygieia, Inc., and the College Diabetes Network.
Before he joined Healthcare Capital, Mr. Brooks served as the President and CEO of the Joslin Diabetes Center, an NIH-designated Diabetes Research Center and non-profit recognized as a leader in diabetes research and treatment and affiliated with the Harvard Medical School. Prior to his time at Joslin, Mr. Brooks co-founded Prism Venture Partners, a $1.25 billion venture capital firm based in the Boston area. Previously, he was also a senior medical device executive with Pfizer and a senior manager with Arthur Andersen & Co.
“I’m excited for the opportunity to lend my experience to WellDoc,” said Mr. Brooks. “The company’s unique approach to the digital healthcare market is intriguing, and I’m looking forward to working with the team.”
A Massachusetts native, Mr. Brooks holds an MSBA in Accounting and Finance and BBA from the University of Massachusetts at Amherst. He is also a Certified Public Accountant.
WellDoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of helping individuals self-manage their conditions to achieve significant clinical outcomes and cost savings. We began our journey by mastering diabetes management solutions and are moving rapidly into creating additional tools for managing other chronic diseases including hypertension, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have taken an aggressive and innovative approach that utilizes sophisticated logic, precise algorithms, and artificial intelligence (AI), which integrates the most advanced mobile technology and behavioral insights. WellDoc partners with, collaborates with, and is backed by top healthcare companies (including Merck and Johnson and Johnson), leading innovators, dedicated investors, and top mobile technology
companies (such as Samsung). For more information, visit www.welldoc.com.